Lipexal

Simvastatin, the active ingredient in Lipexal, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol levels and is used in patients with hypercholesterolemia, including familial forms, and in those at risk of cardiovascular events. It is also indicated for primary and secondary prevention of atherosclerotic disease.

GNH USA supplies Lipexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory adherence, and reliable logistics for global healthcare providers.

Simvastatin is used to manage disorders of lipid metabolism and to reduce cardiovascular risk.

Hypercholesterolemia: lowers total and LDL cholesterol, helping achieve target lipid levels. Familial hypercholesterolemia: reduces genetically elevated LDL cholesterol, supporting long‑term risk reduction. Cardiovascular risk prevention: decreases the incidence of myocardial infarction, stroke and related events in patients with established risk factors. Mixed dyslipidemia: improves lipid profile by reducing triglycerides and modestly raising HDL cholesterol.

Simvastatin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Abdominal discomfort: nausea, dyspepsia or flatulence. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Hepatotoxicity: marked elevation of liver transaminases or jaundice. - Allergic reactions: rash, pruritus or angioedema. - New‑onset diabetes: hyperglycemia in susceptible individuals.

Before initiating Simvastatin therapy, consider the following precautions to ensure safe use. - Liver function: obtain baseline ALT/AST and monitor periodically. - Drug interactions: review concomitant medications that affect CYP3A4. - Renal impairment: adjust use in severe kidney disease. - Pregnancy and lactation: avoid use due to unknown safety. - Muscle disorders: discontinue if unexplained muscle pain or weakness develops. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Simvastatin interacts with several medicines; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors): may cause toxic levels of simvastatin. - Gemfibrozil: increases risk of myopathy and rhabdomyolysis. - Cyclosporine: elevates simvastatin concentrations and muscle toxicity risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect, monitor INR. - Amiodarone: modest increase in simvastatin exposure, observe for muscle symptoms. - Digoxin: potential increase in serum digoxin, check levels.